{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:40:51Z","timestamp":1792518051732,"version":"4.5.0"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82573605"],"award-info":[{"award-number":["82573605"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["12501680"],"award-info":[{"award-number":["12501680"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473403"],"award-info":[{"award-number":["82473403"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82503842"],"award-info":[{"award-number":["82503842"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014103","name":"Key Technology Research and Development Program of Shandong Province","doi-asserted-by":"publisher","award":["2025CXPT130"],"award-info":[{"award-number":["2025CXPT130"]}],"id":[{"id":"10.13039\/100014103","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Shandong Province Natural Science Foundation","doi-asserted-by":"publisher","award":["ZR2025MS1405"],"award-info":[{"award-number":["ZR2025MS1405"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Shandong Province Natural Science Foundation","doi-asserted-by":"publisher","award":["ZR2024QF238"],"award-info":[{"award-number":["ZR2024QF238"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Shandong Province Natural Science Foundation","doi-asserted-by":"publisher","award":["ZR2025QC984"],"award-info":[{"award-number":["ZR2025QC984"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.canlet.2026.218577","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T06:45:18Z","timestamp":1778049918000},"page":"218577","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Levetiracetam reverses temozolomide resistance in glioblastoma by blocking drug efflux through RAB5A\/CD63-RAB35 axis"],"prefix":"10.1016","volume":"652","author":[{"given":"Jixing","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingkun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinran","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhua","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijie","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingtong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongrong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kailiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7787-9330","authenticated-orcid":false,"given":"Gang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2026.218577_bib1","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.canlet.2020.10.050","article-title":"Clinical practice guidelines for the management of adult diffuse gliomas","volume":"499","author":"Jiang","year":"2020","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2026.218577_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217884","article-title":"Mechanisms and therapeutic implications of glioma-neuron interactions","volume":"629","author":"Wang","year":"2025","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2026.218577_bib3","article-title":"Glioblastoma: clinical presentation, diagnosis, and management","volume":"374","author":"McKinnon","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.canlet.2026.218577_bib4","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41572-024-00516-y","article-title":"Glioma","volume":"10","author":"Weller","year":"2024","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.canlet.2026.218577_bib5","doi-asserted-by":"crossref","first-page":"4330","DOI":"10.7150\/thno.71763","article-title":"PTRF\/Cavin-1 enhances chemo-resistance and promotes temozolomide efflux through extracellular vesicles in glioblastoma","volume":"12","author":"Yang","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.canlet.2026.218577_bib6","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/neuonc\/noad159","article-title":"EPIC-1042 as a potent PTRF\/Cavin1-caveolin-1 interaction inhibitor to induce PARP1 autophagic degradation and suppress temozolomide efflux for glioblastoma","volume":"26","author":"Hong","year":"2024","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.canlet.2026.218577_bib7","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/neuonc\/noac216","article-title":"Palliative care and end-of-life care in adults with malignant brain tumors","volume":"25","author":"Koekkoek","year":"2023","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.canlet.2026.218577_bib8","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1158\/0008-5472.CAN-23-0609","article-title":"Neuronal activity promotes glioma progression by inducing Proneural-to-Mesenchymal transition in glioma stem cells","volume":"84","author":"Guo","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218577_bib9","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1158\/1078-0432.CCR-23-0430","article-title":"Hypoxia-induced neuronal activity in glioma patients polarizes microglia by potentiating RNA m6A demethylation","volume":"30","author":"Guo","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218577_bib10","first-page":"e125","article-title":"Effect of levetiracetam use duration on overall survival of isocitrate dehydrogenase wild-type glioblastoma in adults: an observational study","volume":"98","author":"Pallud","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.canlet.2026.218577_bib11","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-67697-w","article-title":"Association between survival and levetiracetam use in glioblastoma patients treated with temozolomide chemoradiotherapy","volume":"10","author":"Roh","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.canlet.2026.218577_bib12","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1002\/cncr.29439","article-title":"Survival benefit of levetiracetam in patients treated with concomitant chemoradiotherapy and adjuvant chemotherapy with temozolomide for glioblastoma multiforme","volume":"121","author":"Kim","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2026.218577_bib13","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1093\/neuonc\/noq044","article-title":"Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide","volume":"12","author":"Bobustuc","year":"2010","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.canlet.2026.218577_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106290","article-title":"Association of plasma levetiracetam concentration, MGMT methylation and sex with survival of chemoradiotherapy-treated glioblastoma patients","volume":"181","author":"Cucchiara","year":"2022","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.canlet.2026.218577_bib15","article-title":"Biological, diagnostic and therapeutic implications of exosomes in glioma","volume":"582","author":"Davidson","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2026.218577_bib16","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nrm.2017.125","article-title":"Shedding light on the cell biology of extracellular vesicles","volume":"19","author":"van Niel","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2026.218577_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.tcb.2023.06.006","article-title":"The ins-and-outs of exosome biogenesis, secretion, and internalization","volume":"34","author":"Arya","year":"2024","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.canlet.2026.218577_bib18","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1126\/science.adf5112","article-title":"The endosome as engineer","volume":"378","author":"Zanellati","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.canlet.2026.218577_bib19","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/s41580-024-00746-8","article-title":"Assembly and fission of tubular carriers mediating protein sorting in endosomes","volume":"25","author":"Gopaldass","year":"2024","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2026.218577_bib20","doi-asserted-by":"crossref","first-page":"6427","DOI":"10.1038\/s41467-021-26018-z","article-title":"RAB5A expression is a predictive biomarker for trastuzumab emtansine in breast cancer","volume":"12","author":"Engebraaten","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218577_bib21","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1038\/s41467-021-21695-2","article-title":"Structural basis for VPS34 kinase activation by Rab1 and Rab5 on membranes","volume":"12","author":"Tremel","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218577_bib22","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12943-019-0990-6","article-title":"Long non-coding RNA HOTAIR promotes exosome secretion by regulating RAB35 and SNAP23 in hepatocellular carcinoma","volume":"18","author":"Yang","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2026.218577_bib23","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1080\/15548627.2023.2210446","article-title":"Secretory autophagy-promoted cargo exocytosis requires active RAB37","volume":"20","author":"Wu","year":"2024","journal-title":"Autophagy"},{"key":"10.1016\/j.canlet.2026.218577_bib24","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12465","article-title":"Stress-induced Rab11a-exosomes induce amphiregulin-mediated cetuximab resistance in colorectal cancer","volume":"13","author":"Mason","year":"2024","journal-title":"J. Extracell. Vesicles"},{"key":"10.1016\/j.canlet.2026.218577_bib25","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/s41556-024-01432-9","article-title":"CD63 sorts cholesterol into endosomes for storage and distribution via exosomes","volume":"26","author":"Palmulli","year":"2024","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.canlet.2026.218577_bib26","doi-asserted-by":"crossref","DOI":"10.3402\/jev.v5.31295","article-title":"Nanoparticle analysis sheds budding insights into genetic drivers of extracellular vesicle biogenesis","volume":"5","author":"Hurwitz","year":"2016","journal-title":"J. Extracell. Vesicles"},{"key":"10.1016\/j.canlet.2026.218577_bib27","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.3389\/fmicb.2017.01653","article-title":"Rab3a-Bound CD63 is degraded and Rab3a-Free CD63 is incorporated into HIV-1 particles","volume":"8","author":"Kubo","year":"2017","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.canlet.2026.218577_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216812","article-title":"EPIC-0628 abrogates HOTAIR\/EZH2 interaction and enhances the temozolomide efficacy via promoting ATF3 expression and inhibiting DNA damage repair in glioblastoma","volume":"588","author":"Yang","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2026.218577_bib29","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1002\/cac2.12502","article-title":"Blockage of EGFR\/AKT and mevalonate pathways synergize the antitumor effect of temozolomide by reprogramming energy metabolism in glioblastoma","volume":"43","author":"Cui","year":"2023","journal-title":"Cancer Commun."},{"key":"10.1016\/j.canlet.2026.218577_bib30","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.7150\/thno.92703","article-title":"CRISPR-Cas9 library screening combined with an exosome-targeted delivery system addresses tumorigenesis\/TMZ resistance in the mesenchymal subtype of glioblastoma","volume":"14","author":"Zhao","year":"2024","journal-title":"Theranostics"},{"key":"10.1016\/j.canlet.2026.218577_bib31","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.gpb.2022.01.004","article-title":"SynergyFinder plus: toward better interpretation and annotation of drug combination screening datasets","volume":"20","author":"Zheng","year":"2022","journal-title":"Genom. Proteom. Bioinform."},{"key":"10.1016\/j.canlet.2026.218577_bib32","doi-asserted-by":"crossref","first-page":"7032","DOI":"10.7150\/thno.74197","article-title":"TCA-phospholipid-glycolysis targeted triple therapy effectively suppresses ATP production and tumor growth in glioblastoma","volume":"12","author":"Yang","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.canlet.2026.218577_bib33","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","article-title":"EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood","volume":"18","author":"Weller","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218577_bib34","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218577_bib35","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1308573","article-title":"A randomized trial of bevacizumab for newly diagnosed glioblastoma","volume":"370","author":"Gilbert","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218577_bib36","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma","volume":"370","author":"Chinot","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218577_bib37","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S1470-2045(17)30517-X","article-title":"Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial","volume":"18","author":"Weller","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2026.218577_bib38","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1093\/neuonc\/noac116","article-title":"Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter","volume":"24","author":"Lim","year":"2022","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.canlet.2026.218577_bib39","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","article-title":"Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial","volume":"6","author":"Reardon","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.canlet.2026.218577_bib40","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/neuonc\/noac242","article-title":"A novel compound EPIC-0412 reverses temozolomide resistance via inhibiting DNA repair\/MGMT in glioblastoma","volume":"25","author":"Zhao","year":"2023","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.canlet.2026.218577_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2022.100905","article-title":"ABC transporters affects tumor immune microenvironment to regulate cancer immunotherapy and multidrug resistance","volume":"66","author":"Fan","year":"2023","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.canlet.2026.218577_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2022.100913","article-title":"CHD4 promotes acquired chemoresistance and tumor progression by activating the MEK\/ERK axis","volume":"66","author":"Wu","year":"2023","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.canlet.2026.218577_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2024.101100","article-title":"Lansoprazole (LPZ) reverses multidrug resistance (MDR) in cancer through impeding ATP-binding cassette (ABC) transporter-mediated chemotherapeutic drug efflux and lysosomal sequestration","volume":"76","author":"Ji","year":"2024","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.canlet.2026.218577_bib44","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/21541248.2016.1264352","article-title":"New insights into the function of Rab GTPases in the context of exosomal secretion","volume":"9","author":"Blanc","year":"2018","journal-title":"Small GTPases"},{"key":"10.1016\/j.canlet.2026.218577_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/v13040675","article-title":"Epstein-Barr virus LMP1 modulates the CD63 interactome","volume":"13","author":"Cheerathodi","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.canlet.2026.218577_bib46","article-title":"Clinical diagnosis and perioperative management of glioma-related epilepsy","volume":"10","author":"You","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2026.218577_bib47","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s11060-017-2660-0","article-title":"Efficacy and safety of Levetiracetam vs. other antiepileptic drugs in Hispanic patients with glioblastoma","volume":"136","author":"Cardona","year":"2018","journal-title":"J. Neuro Oncol."},{"key":"10.1016\/j.canlet.2026.218577_bib48","doi-asserted-by":"crossref","first-page":"9861","DOI":"10.1073\/pnas.0308208101","article-title":"The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam","volume":"101","author":"Lynch","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2026.218577_bib49","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s40263-016-0384-x","article-title":"Synaptic vesicle glycoprotein 2A ligands in the treatment of epilepsy and beyond","volume":"30","author":"L\u00f6scher","year":"2016","journal-title":"CNS Drugs"},{"key":"10.1016\/j.canlet.2026.218577_bib50","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/neuonc\/nop028","article-title":"Expression of synaptic vesicle protein 2A in epilepsy-associated brain tumors and in the peritumoral cortex","volume":"12","author":"de Groot","year":"2010","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.canlet.2026.218577_bib51","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-33282-5","article-title":"Aberrant neuronal differentiation is common in glioma but is associated neither with epileptic seizures nor with better survival","volume":"8","author":"Beier","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.canlet.2026.218577_bib52","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1093\/neuonc\/noaa104","article-title":"Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial","volume":"22","author":"Hanna","year":"2020","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.canlet.2026.218577_bib53","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1093\/neuonc\/noab111","article-title":"A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study","volume":"23","author":"Sim","year":"2021","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.canlet.2026.218577_bib54","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1001\/jamaoncol.2024.4361","article-title":"Efficacy of adding veliparib to temozolomide for patients with MGMT-methylated glioblastoma: a randomized clinical trial","volume":"10","author":"Sarkaria","year":"2024","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.canlet.2026.218577_bib55","doi-asserted-by":"crossref","first-page":"707","DOI":"10.2165\/00003088-200443110-00002","article-title":"Clinical pharmacokinetics of levetiracetam","volume":"43","author":"Patsalos","year":"2004","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.canlet.2026.218577_bib56","series-title":"EPAR Product Information","year":"2015"},{"key":"10.1016\/j.canlet.2026.218577_bib57","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/sj.bjp.0704141","article-title":"A microdialysis study of the novel antiepileptic drug levetiracetam: extracellular pharmacokinetics and effect on taurine in rat brain","volume":"133","author":"Tong","year":"2001","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.canlet.2026.218577_bib58","article-title":"Valproic acid reverses macrophage-mediated temozolomide resistance in macrophage-rich gliomas","volume":"10","author":"Ni","year":"2026","journal-title":"npj Precis. Oncol."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030438352600340X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030438352600340X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:02:26Z","timestamp":1792515746000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030438352600340X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":58,"alternative-id":["S030438352600340X"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218577","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Levetiracetam reverses temozolomide resistance in glioblastoma by blocking drug efflux through RAB5A\/CD63-RAB35 axis","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218577","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"218577"}}